Patents by Inventor Rob Lavigne

Rob Lavigne has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11725212
    Abstract: It is a first object of the present invention to provide a method for preparing a Tile vector, being a vector, which comprises a selectable marker and a coding polynucleotide, wherein said coding polynucleotide is immediately preceded and followed by a type IIs recognition sequence, wherein said preceding and following recognition sequences are recognized by a same type IIs restriction enzyme, but have an opposite orientation. More particularly, the position and orientation of said preceding and following type IIs recognition sequences provides for the cleavage of said Tile vector by a corresponding type IIs restriction enzyme resulting in the release of said coding polynucleotide sequence having at its respective ends overhang sequences with a known orientation and length, while lacking said preceding and following type IIs recognition sequences.
    Type: Grant
    Filed: December 19, 2017
    Date of Patent: August 15, 2023
    Assignees: Universiteit Gent, Katholieke Universiteit Leuven
    Inventors: Dennis Grimon, Hans Gerstmans, Yves Briers, Rob Lavigne
  • Patent number: 11052137
    Abstract: The application relates to antimicrobial agents against Gram-negative bacteria, in particular to fusion proteins composed of an enzyme having the activity of degrading the cell wall of Gram-negative bacteria and a peptide stretch fused to the enzyme at the N- or C-terminus, as well as pharmaceutical compositions comprising the same. Moreover, it relates to nucleic acid molecules encoding such a fusion protein, vectors comprising said nucleic acid molecules and host cells comprising either said nucleic acid molecules or said vectors. In addition, it relates to such a fusion protein for use as a medicament, in particular for the treatment or prevention of Gram-negative bacterial infections, as diagnostic means or as cosmetic substance. The application also relates to the treatment or prevention of Gram-negative bacterial contamination of foodstuff, of food processing equipment, of food processing plants, of surfaces coming into contact with foodstuff, of medical devices, of surfaces in hospitals and surgeries.
    Type: Grant
    Filed: October 24, 2018
    Date of Patent: July 6, 2021
    Assignees: LYSANDO AG, KATHOLIEKE UNIVERSITES LEUVEN, K.U. LEUVEN R&D
    Inventors: Rob Lavigne, Stefan Miller, Yves Briers, Guido Volckaert, Maarten Walmagh
  • Publication number: 20200199554
    Abstract: The present invention relates to a group of proteins from bacterial phages which show DNA degrading activity.
    Type: Application
    Filed: July 26, 2018
    Publication date: June 25, 2020
    Inventors: Abram Aertsen, Hanne Hendrix, Rob Lavigne, Marie Van Der Gucht
  • Publication number: 20190323017
    Abstract: It is a first object of the present invention to provide a method for preparing a Tile vector, being a vector, which comprises a selectable marker and a coding polynucleotide, wherein said coding polynucleotide is immediately preceded and followed by a type Ms recognition sequence, wherein said preceding and following recognition sequences are recognized by a same type lis restriction enzyme, but have an opposite orientation. More particularly, the position and orientation of said preceding and following type lis recognition sequences provides for the cleavage of said Tile vector by a corresponding type lis restriction enzyme resulting in the release of said coding polynucleotide sequence having at its respective ends overhang sequences with a known orientation and length, while lacking said preceding and following type Ms recognition sequences.
    Type: Application
    Filed: December 19, 2017
    Publication date: October 24, 2019
    Applicants: Universiteit Gent, Katholieke Universiteit Leuven
    Inventors: Dennis Grimon, Hans Gerstmans, Yves Briers, Rob Lavigne
  • Publication number: 20190209663
    Abstract: The application relates to antimicrobial agents against Gram-negative bacteria, in particular to fusion proteins composed of an enzyme having the activity of degrading the cell wall of Gram-negative bacteria and a peptide stretch fused to the enzyme at the N- or C-terminus, as well as pharmaceutical compositions comprising the same. Moreover, it relates to nucleic acid molecules encoding such a fusion protein, vectors comprising said nucleic acid molecules and host cells comprising either said nucleic acid molecules or said vectors. In addition, it relates to such a fusion protein for use as a medicament, in particular for the treatment or prevention of Gram-negative bacterial infections, as diagnostic means or as cosmetic substance. The application also relates to the treatment or prevention of Gram-negative bacterial contamination of foodstuff, of food processing equipment, of food processing plants, of surfaces coming into contact with foodstuff, of medical devices, of surfaces in hospitals and surgeries.
    Type: Application
    Filed: October 24, 2018
    Publication date: July 11, 2019
    Applicants: LYSANDO AG, KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D
    Inventors: Rob Lavigne, Stefan Miller, Yves Briers, Guido Volckaert, Maarten Walmagh
  • Patent number: 10329550
    Abstract: The present invention relates to polypeptides comprising an amino sequence selected from the group consisting of: SEQ ID NO: 1, and fragments and derivatives of these. The invention also relates to the corresponding nucleic acids vectors, host cells and compositions. The present inventions also relates to the use of said polypeptides, nucleic acids, vectors, host cells and compositions in a method for treatment of the human or animal body by surgery or therapy or in diagnostic methods practiced on the human or animal body, in particular for the treatment or prevention of Gram-negative bacterial infections. The polypeptides, nucleic acids, vectors, host cells and compositions according to the invention may also be used as an antimicrobial in food or feed, or in cosmetics, as disinfecting agent or in the environmental field.
    Type: Grant
    Filed: February 13, 2015
    Date of Patent: June 25, 2019
    Assignee: LYSANDO AG
    Inventors: Yves Briers, Rob Lavigne, Martin Griessl
  • Patent number: 10137175
    Abstract: The application relates to antimicrobial agents against Gram-negative bacteria, in particular to fusion proteins composed of an enzyme having the activity of degrading the cell wall of Gram-negative bacteria and a peptide stretch fused to the enzyme at the N- or C-terminus, as well as pharmaceutical compositions comprising the same. Moreover, it relates to nucleic acid molecules encoding such a fusion protein, vectors comprising said nucleic acid molecules and host cells comprising either said nucleic acid molecules or said vectors. In addition, it relates to such a fusion protein for use as a medicament, in particular for the treatment or prevention of Gram-negative bacterial infections, as diagnostic means or as cosmetic substance. The application also relates to the treatment or prevention of Gram-negative bacterial contamination of foodstuff, of food processing equipment, of food processing plants, of surfaces coming into contact with foodstuff, of medical devices, of surfaces in hospitals and surgeries.
    Type: Grant
    Filed: November 7, 2014
    Date of Patent: November 27, 2018
    Assignees: LYSANDO AG, KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D
    Inventors: Rob Lavigne, Stefan Miller, Yves Briers, Guido Volckaert, Maarten Walmagh
  • Patent number: 9809808
    Abstract: The present invention relates to endolysin variants comprising an endolysin to which a peptide stretch with membrane or LPS disrupting activity is fused. Moreover, the present invention relates to nucleic acid molecules encoding said modified endolysin variant, vectors comprising said nucleic acid molecules and host cells comprising either said nucleic acid molecules or said vectors. In addition, the present invention relates to a method for producing said endolysin variant. Further, the present invention relates to said modified endolysin variant for use as a medicament, in particular for the treatment or prevention of Gram-negative bacterial infections, as diagnostic means, disinfectant or as cosmetic substance. The present invention also relates to the removal or reduction or prevention of Gram-negative bacterial contamination of foodstuff, of food processing equipment, of food processing plants, of surfaces coming into contact with foodstuff, of medical devices, of surfaces in hospitals and surgeries.
    Type: Grant
    Filed: August 25, 2009
    Date of Patent: November 7, 2017
    Assignee: KATHOLIEKE UNIVERSITEIT LEUVEN K.U. LEUVEN R&D
    Inventors: Yves Briers, Rob Lavigne, Guido Volckaert
  • Publication number: 20170106058
    Abstract: The present invention relates to a polypeptide comprising a peptidoglycan hydrolase for use as a medicament for the treatment of chronic bacterial infections. The present invention further relates to a polypeptide comprising a peptidoglycan hydrolase comprising an endopeptidase, N-acetyl-muramoyl-L-alanine-amidase, N-acetyl-muramidase, N-acetyl-glucosaminidase and/or lytic transglycosylase.
    Type: Application
    Filed: April 8, 2015
    Publication date: April 20, 2017
    Inventors: Stefan MILLER, Yves BRIERS, Rob LAVIGNE
  • Publication number: 20170051266
    Abstract: The present invention relates to polypeptides comprising an amino sequence selected from the group consisting of: SEQ ID NO: 1, and fragments and derivatives of these. The invention also relates to the corresponding nucleic acids vectors, host cells and compositions. The present inventions also relates to the use of said polypeptides, nucleic acids, vectors, host cells and compositions in a method for treatment of the human or animal body by surgery or therapy or in diagnostic methods practiced on the human or animal body, in particular for the treatment or prevention of Gram-negative bacterial infections. The polypeptides, nucleic acids, vectors, host cells and compositions according to the invention may also be used as an antimicrobial in food or feed, or in cosmetics, as disinfecting agent or in the environmental field.
    Type: Application
    Filed: February 13, 2015
    Publication date: February 23, 2017
    Applicant: Lysando AG
    Inventors: Yves BRIERS, Rob LAVIGNE, Martin GRIESSL
  • Publication number: 20160010071
    Abstract: The present invention relates to a polypeptide with an amino acid sequence according to SEQ ID NO: 1 and fragments or derivatives thereof. The present invention further relates to fusion proteins comprising said polypeptide and an additional peptide stretch fused to said polypeptide at the N- or C-terminus. Moreover, the present invention relates to nucleic acid molecules encoding said polypeptide or fusion protein, vectors comprising said nucleic acid molecules and host cells comprising either said nucleic acid molecules or said vectors. In addition, the present invention relates to said polypeptide or fusion protein for use as a medicament, in particular for the treatment or prevention of Gram-negative bacterial infections, as diagnostic means, as cosmetic substance or as sanitizing agent.
    Type: Application
    Filed: October 1, 2015
    Publication date: January 14, 2016
    Inventors: Yves BRIERS, Rob LAVIGNE, Maarten WALMAGH, Stefan MILLER
  • Patent number: 9169472
    Abstract: The present invention relates to a polypeptide with an amino acid sequence according to SEQ ID NO: 1 and fragments or derivatives thereof. The present invention further relates to fusion proteins comprising said polypeptide and an additional peptide stretch fused to said polypeptide at the N- or C-terminus. Moreover, the present invention relates to nucleic acid molecules encoding said polypeptide or fusion protein, vectors comprising said nucleic acid molecules and host cells comprising either said nucleic acid molecules or said vectors. In addition, the present invention relates to said polypeptide or fusion protein for use as a medicament, in particular for the treatment or prevention of Gram-negative bacterial infections, as diagnostic means, as cosmetic substance or as sanitizing agent.
    Type: Grant
    Filed: September 3, 2014
    Date of Patent: October 27, 2015
    Assignees: LYSANDO AG, KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D
    Inventors: Yves Briers, Rob Lavigne, Maarten Walmagh, Stefan Miller
  • Publication number: 20150118731
    Abstract: The application relates to antimicrobial agents against Gram-negative bacteria, in particular to fusion proteins composed of an enzyme having the activity of degrading the cell wall of Gram-negative bacteria and a peptide stretch fused to the enzyme at the N- or C-terminus, as well as pharmaceutical compositions comprising the same. Moreover, it relates to nucleic acid molecules encoding such a fusion protein, vectors comprising said nucleic acid molecules and host cells comprising either said nucleic acid molecules or said vectors. In addition, it relates to such a fusion protein for use as a medicament, in particular for the treatment or prevention of Gram-negative bacterial infections, as diagnostic means or as cosmetic substance. The application also relates to the treatment or prevention of Gram-negative bacterial contamination of foodstuff, of food processing equipment, of food processing plants, of surfaces coming into contact with foodstuff, of medical devices, of surfaces in hospitals and surgeries.
    Type: Application
    Filed: November 7, 2014
    Publication date: April 30, 2015
    Applicants: LYSANDO AG, KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D
    Inventors: Rob LAVIGNE, Stefan MILLER, Yves BRIERS, Guido VOLCKAERT, Maarten WALMAGH
  • Publication number: 20150024469
    Abstract: The present invention relates to a polypeptide with an amino acid sequence according to SEQ ID NO: 1 and fragments or derivatives thereof. The present invention further relates to fusion proteins comprising said polypeptide and an additional peptide stretch fused to said polypeptide at the N- or C-terminus. Moreover, the present invention relates to nucleic acid molecules encoding said polypeptide or fusion protein, vectors comprising said nucleic acid molecules and host cells comprising either said nucleic acid molecules or said vectors. In addition, the present invention relates to said polypeptide or fusion protein for use as a medicament, in particular for the treatment or prevention of Gram-negative bacterial infections, as diagnostic means, as cosmetic substance or as sanitizing agent.
    Type: Application
    Filed: September 3, 2014
    Publication date: January 22, 2015
    Applicants: LYSANDO AG, KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D
    Inventors: Yves BRIERS, Rob LAVIGNE, Maarten WALMAGH, Stefan MILLER
  • Patent number: 8906365
    Abstract: The application relates to antimicrobial agents against Gram-negative bacteria, in particular to fusion proteins composed of an enzyme having the activity of degrading the cell wall of Gram-negative bacteria and a peptide stretch fused to the enzyme at the N- or C-terminus, as well as pharmaceutical compositions thereof. Moreover, it relates to nucleic acid molecules encoding such a fusion protein, vectors carrying the nucleic acid molecules and host cells transformed with either the nucleic acid molecules or the vectors. In addition, it relates to such a fusion protein for use as a medicament, in particular for the treatment or prevention of Gram-negative bacterial infections, as diagnostic means or as cosmetic substance. The application also relates to the treatment or prevention of Gram-negative bacterial contamination of foodstuff, of food processing equipment, of food processing plants, of surfaces coming into contact with foodstuff, of medical devices, of surfaces in hospitals and surgeries.
    Type: Grant
    Filed: June 28, 2010
    Date of Patent: December 9, 2014
    Assignees: Lysando AG, Katholieke Universiteit Leuven, K.U. Leuven R&D
    Inventors: Rob Lavigne, Stefan Miller, Yves Briers, Guido Volckaert, Maarten Walmagh
  • Patent number: 8846865
    Abstract: The present invention relates to a polypeptide with an amino acid sequence according to SEQ ID NO: 1 and fragments or derivatives thereof. The present invention further relates to fusion proteins comprising said polypeptide and an additional peptide stretch fused to said polypeptide at the N- or C-terminus. Moreover, the present invention relates to nucleic acid molecules encoding said polypeptide or fusion protein, vectors comprising said nucleic acid molecules and host cells comprising either said nucleic acid molecules or said vectors. In addition, the present invention relates to said polypeptide or fusion protein for use as a medicament, in particular for the treatment or prevention of Gram-negative bacterial infections, as diagnostic means, as cosmetic substance or as sanitizing agent.
    Type: Grant
    Filed: August 24, 2010
    Date of Patent: September 30, 2014
    Assignees: Lysando AG, Katholieke Universiteit Leuven, K.U. Leuven R&D
    Inventors: Yves Briers, Rob Lavigne, Maarten Walmagh, Stefan Miller
  • Publication number: 20140017224
    Abstract: The present invention relates to a polypeptide with endolysin activity comprising an amino acid sequence according to SEQ ID No. 1 and fragments or derivatives thereof, or fusion proteins derived thereof. Moreover, the present invention relates to nucleic acid molecules encoding said polypeptide or fusion protein, vectors comprising said nucleic acid molecules and host cells comprising either said nucleic acid molecules or said vectors. In addition, the present invention relates to said polypeptide, fragment, derivative or fusion protein for use as a medicament, in particular for the treatment or prevention of Gram-negative bacterial infections, as diagnostic means, as cosmetic substance or as sanitizing agent.
    Type: Application
    Filed: November 3, 2011
    Publication date: January 16, 2014
    Applicants: UNIVERSITY OF MINHO, KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D
    Inventors: Joana Cecilia Valente Rodrigues Azeredo, Silvio Roberto Branco Dos Santos, Leonardus Dorothea Kluskens, Rob Lavigne, Maarten Walmagh
  • Publication number: 20130344055
    Abstract: The present invention relates to a fusion protein composed of an enzyme having the activity of degrading the cell wall of Gram-negative bacteria and/or Gram-positive bacteria and at least two peptide stretches fused to the enzyme at the N- or C-terminus, wherein the peptide stretches are distinct and selected from the group of synthetic amphiphatic peptide, synthetic cationic peptide, synthetic polycationic peptide, synthetic hydrophobic peptide, or naturally occurring antimicrobial peptide, like sushi peptide and defensin. Moreover, the present invention relates to nucleic acid molecules encoding said fusion protein, vectors comprising said nucleic acid molecules and host cells comprising either said nucleic acid molecules or said vectors. In addition, the present invention relates to said fusion protein for use as a medicament, diagnostic means, cosmetic substance, a disinfectant or a food additive.
    Type: Application
    Filed: December 23, 2011
    Publication date: December 26, 2013
    Applicants: KATHOLIEKE UNIVERSITEIT LEUVEN, LYSANDO AG
    Inventors: Yves Briers, Rob Lavigne, Maarten Walmagh, Stefan Miller
  • Publication number: 20120189606
    Abstract: The present invention relates to antimicrobial agents against Gram-negative bacteria, in particular to fusion proteins composed of an enzyme having the activity of degrading the cell wall of Gram-negative bacteria and a peptide stretch fused to the enzyme at the N- or C-terminus. Moreover, the present invention relates to nucleic acid molecules encoding said fusion protein, vectors comprising said nucleic acid molecules and host cells comprising either said nucleic acid molecules or said vectors. In addition, the present invention relates to said fusion protein for use as a medicament, in particular for the treatment or prevention of Gram-negative bacterial infections, as diagnostic means or as cosmetic substance. The present invention also relates to the treatment or prevention of Gram-negative bacterial contamination of foodstuff, of food processing equipment, of food processing plants, of surfaces coming into contact with foodstuff, of medical devices, of surfaces in hospitals and surgeries.
    Type: Application
    Filed: June 28, 2010
    Publication date: July 26, 2012
    Inventors: Rob Lavigne, Stefan Miller, Yves Briers, Guido Volckaert, Maarten Walmagh
  • Publication number: 20120189608
    Abstract: The present invention relates to a polypeptide with an amino acid sequence according to SEQ ID NO: 1 and fragments or derivatives thereof. The present invention further relates to fusion proteins comprising said polypeptide and an additional peptide stretch fused to said polypeptide at the N- or C-terminus. Moreover, the present invention relates to nucleic acid molecules encoding said polypeptide or fusion protein, vectors comprising said nucleic acid molecules and host cells comprising either said nucleic acid molecules or said vectors. In addition, the present invention relates to said polypeptide or fusion protein for use as a medicament, in particular for the treatment or prevention of Gram-negative bacterial infections, as diagnostic means, as cosmetic substance or as sanitizing agent.
    Type: Application
    Filed: August 24, 2010
    Publication date: July 26, 2012
    Inventors: Yves Briers, Rob Lavigne, Maarten Walmagh, Stefan Miller